BMJ
L
1046/j
Summary Background Previously, a double‐blind, randomized, multicentre study (LION study) compared the efficacy of continuous terbinafine 250 mg daily E Glyn V Evans, BÆrdur Sigurgeirsson for the LION study group Abstract Objective To compare the efficacy and safety of continuous terbinafine with intermittent itraconazole
Itraconazole in Onychomycosis (LION) study whose results were published in 1999
In a 1998 study 30 of 378 patients with dermatophytic onychomycosis, continuous terbinafine therapy was shown to be more effective than continuous
Menu
Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis
1999 Apr 17; 318(7190):1031-5
Mycological and clinical relapse rates were significantly higher in itraconazole vs terbinafine-treated patients (53% vs 23% and 48%
for the LION study group
Setting: 35 centres in six European countries
A median of 57 resected lymph nodes was Once-weekly fluconazole (450 mg) for 4, 6, or 9 months of treatment for distal subungual onychomycosis of the toenail
Combination therapy with oral terbinafine or itraconazole and K101 nail solution results in clearance of infected nail earlier than that with topical K101 alone, and these combinations may encourage compliance and be effective for patients with moderate onychomycosis
albicans infection achieved a negative mycological culture at the end of study (week 48) after treatment with
A lion's pride
The LION Study Group Evans, E
1031 Search worldwide, life-sciences literature Search
Guidelines for treatment of
CrossRef View in Scopus Google Scholar